Medical Affairs Outsourcing Market Size Share, Report 2026 To 2035
Medical Affairs Outsourcing Market (By Service: Medical Writing & Publishing, Medical Monitoring, Medical Science Liaisons (MSLs), Medical Information, Others; By End User: Pharmaceutical, Biopharmaceutical, Medical Devices) - Global Industry Analysis, Size, Share, Regional Analysis, Trends and Forecast 2026 to 2035
- Last Updated: 10 Jun 2026
- Report Code: ARC1714
- Category: Healthcare and Pharmaceuticals
Medical Affairs Outsourcing Market Size, Forecast 2026 to 2035
The global medical affairs outsourcing market size was valued at $2.81 billion in 2025 and it is estimated to surpass $8.99 billion by 2035; growing at a CAGR of 12.3% during the forecast period from 2026 to 2035. The medical affairs outsourcing market is expected to boom, on account of increased outsourcing of scientific communication, regulatory support, pharmacovigilance, and medical information services by pharma and biotech firms to boost operational efficiency and cut costs.

Report Highlights
- The North America medical affairs outsourcing market value stood at approximately 37.50% in 2025, owing to strong presence of key pharmaceutical firms, robust healthcare infrastructure, rise in clinical trial activities and increasing need for expert medical communications and regulatory support services across the region.
- The Asia-Pacific medical affairs outsourcing market growth is predicted to register a CAGR of 15.3% during the forecast period, fueled by the booming pharma manufacturing and increasing healthcare investment in countries like China, India and South Korea, leading to rising trend of outsourced medical affairs services, coupled with escalating activities in the clinical research segment.
- In terms of services, medical writing & publishing sub-segment contributed 28% share to medical affairs outsourcing market in 2025 due to escalating demand for clinical study reports, regulatory documentation, scientific publications, and other medical content generation for product approvals and stakeholder interactions.
- By services, the medical monitoring segment held 22% share in 2025 owing to rising emphasis over telehealth platforms and point-of-care testing services.
- The pharmaceutical segment contributed 52% share in 2025 based on industry, driven by the increasing drug development complexity and regulatory rigor along with greater dependence on external expertise for medical communication, pharmacovigilance, and lifecycle management endeavors.
- By end user, the biopharmaceutical segment is expected to grow at 15.3% CAGR during the forecast period as they heavily rely on reducing costs and access to specialized expertise during the entire drug lifecycle.
Market Dynamics
Market Driver
Growing Complexity of Medical Technologies and Treatments requiring Expert Capabilities
The escalating complexity of novel medical technologies, biologics, cell and gene therapies, and precision medicine is a significant driver for the growth of the medical affairs outsourcing market. Due to the highly technical nature of modern therapies, pharmaceutical and biopharmaceutical companies are increasingly entrusting the management of scientific communication, medical information, clinical support, and regulatory affairs to specialized external service providers. The accelerated expansion of oncology, orphan disease treatment, immunotherapy, and personalized medicine also heightened the demand for expert medical affairs personnel proficient in navigating scientific engagement with both healthcare professionals and regulatory authorities. Increasing requirements for generation of real-world evidence (RWE) and post-marketing surveillance, along with an increasing demand for Medical Science Liaisons (MSLs), further encourages outsourcing specialized medical affairs functions to external vendors.
Market Restraint
Data Security and Confidentiality in Outsourced Operations
Concerns regarding data security and confidentiality have emerged as major constraints within the medical affairs outsourcing market, due to the extremely sensitive nature of the pharmaceutical, clinical, and patient data handled. Outsourcing medical affairs functions is known to entail sharing of sensitive intellectual property, clinical trial data, company research data and confidential regulatory documents with external third party service providers.
The occurrence of data breach or improper data management could result in significant financial loss, brand damage and regulatory penalties to the biopharmaceutical companies. Additionally, growing stringent data protection laws and patient privacy regulations globally make it essential for companies to review the security framework and compliance capabilities of their outsourcing partners carefully before entering into any long term association.
Market Opportunity
Growth in Personalized Medicine and Precision Therapeutics demanding medical affairs support
The accelerated growth of personalized medicine, targeted therapeutics and precision medicine is presenting extensive growth opportunities for the medical affairs outsourcing market. Personalized medicine utilizes cutting-edge therapies like gene therapy, CAR-T cell treatment, biomarker-directed oncology drugs, and rare disease medications, all of which demand specialized communication and stakeholder engagement strategies. Medical affairs outsourcing providers are increasingly helping pharmaceutical companies in areas of medical education, evidence development, patient engagement and medical professional training. Rising patient-centricity and growth of personalized healthcare treatments are expected to continue the momentum.
Regional Insights
Why does North America dominates in the medical affairs outsourcing market?
The medical affairs outsourcing market in North America held the leading position in 2025 and accounted for nearly 37.50% of the total market share. Key factors for the region's dominant position include, well-established healthcare infrastructure, dominance of leading pharmaceutical and biotechnology companies, and a developed regulatory landscape.
Rising number of clinical trials and growing product pipeline is creating more demand for specialized medical communications, medical information services, regulatory support and scientific engagement activities, thereby increasing the pace of outsourcing in the region. Further, pharmaceutical companies are tying up with outsourcing providers in order to improve the efficiency of operations, hasten product commercialization, and meet evolving regulatory guidelines.
U.S. Medical Affairs Outsourcing Market
One of the largest and mature medical affairs outsourcing market globally is the U.S. This market is characterized by presence of the numerous multinational pharmaceutical companies, mature biotechnology sector and robust clinical research infrastructure across the country. With increasing complexities of drug development in oncology, immunology, rare diseases, biologics and others the demand for outsourced medical affairs services such as medical writing, pharmacovigilance, MSL support, regulatory communication, generation of real-world evidence is increasing at a fast pace. In addition to it, growing numbers of FDA approvals and larger clinical trial pipelines is providing incentive for pharmaceutical companies to tie up with specialized outsourcing providers for enhanced operational efficiency and quicker commercialization.

Why is Asia Pacific fastest growing region in the medical affairs outsourcing market?
Asia Pacific medical affairs outsourcing market is expected to be the fastest growing region in the world and register a CAGR of 15.3% over the forecast period. Key factors for the growth in this region include growing pharmaceutical manufacturing infrastructure and a rapid increase in healthcare spending and life sciences research across countries like China, India, Japan, and South Korea.
This growth has been boosted by an increase in the number of clinical trials, increasing patient population, and the rise in efforts to achieve regulatory compliance. Companies are outsourcing their medical affairs activities to specialized third-party providers due to these trends. Further, cost advantages and a proficient workforce, as well as supportive government initiatives, and well-developed healthcare infrastructure and research programs are contributing factors.
India Medical Affairs Outsourcing Market
The Indian medical affairs outsourcing market is experiencing rapid growth, attributed to growing pharmaceutical manufacturing sector, enhanced clinical research activities and increasing demand for cost-effective health support services from across the globe. It has evolved as one of the favorite destinations for pharmaceutical and biotechnology companies in terms of outsourcing due to the presence of a huge pool of well-trained medical and scientific professionals, who are well-conversant with English language. The outsourcing market has witnessed a rising demand for medical writing, regulatory support, pharmacovigilance, medical communications and clinical data management services from international pharmaceutical clients increasing their operational reach across Asia-Pacific region.
Segmental Insights
Services Insights
Medical writing and publishing was the largest segment of medical affairs outsourcing with28% share in 2025, which was attributed to growing requirement for scientific writing and publishing, regulatory filing, clinical study reports, publication planning, medical communications and non-promotional materials to support the commercialization of pharmaceutical and biotechnology products. Pharmaceutical companies are increasingly outsourcing their medical writing activities to external service providers for effective function of writing, collecting and preparing registration, submission and other regulatory documents, developing and authoring manuscripts, preparing different medical materials and study reports during drug development phase and commercialization stage.
These external service providers are providing comprehensive writing and scientific publications services, particularly with the increasing number of clinical trials, regulatory filings, and post marketing clinical studies, resulting in high levels of demand for professional writers with the ability to prepare and compose complex scientific and technical papers for multiple publications in various formats. Furthermore, increasing demand for publication planning and evidence based medical communications and the reporting of real world data is further strengthening the market dominance of this segment globally.

The medical monitoring segment held 22% share in 2025 and is expected to see significant growth during the forecast period, driven by the need for accurate and scientific communication, patient support and engagement services, and increasing focus from manufacturers on customer services such as answering all inquiries on medicines’ safety, dosing, and clinical information and drug product information quickly and in line with compliance requirements. While continued rapid growth in digital healthcare, telemedicine, and multi- channel communications is further boosting the demand from pharmaceutical companies for outsourced medical monitoring services that can provide global, multi-language, and 24/7 responsiveness, increasing patient awareness, growing post-market surveillance activities, and focus on patient centricity will contribute to high long-term growth.
End User Insights
The dominant player in the medical affairs outsourcing market is the pharmaceutical industry with 52% share in 2025, which is primarily driven by various factors such as increasing inherent complexities involved in drug development process, increasing regulatory requirements and the increased focus of the pharmaceutical companies towards scientific support during the whole drug lifecycle. There is a high dependence of the pharmaceutical companies on outsourced medical affairs services for several activities such as medical writing, pharmacovigilance & regulatory support, publication planning and medical science liaison activities with the objective of maximizing their operating efficiencies and reducing their internal resource burden.
The ongoing trends such as the ascendancy of specialty drugs, biologics, oncology drugs and orphan diseases demanding more scientific attention as well as increase in the global clinical activities and post-marketing surveillance activities are significantly playing the role of prime factors in strengthening the dominance of the pharmaceutical segment in the global medical affairs market.

Biopharmaceutical market segment is expected to witness significant growth at 15.3% CAGR due to the rapid proliferation of biologics, biosimilars, gene therapies and advanced cell-based therapies across the healthcare industry. Since the development of biopharmaceuticals is complex, there exists a significant need for scientific communication, regulatory support and medical affairs activities that has been favouring the outsourcing trend in this particular market segment.
Other drivers contributing to market growth include increasing number of biologic approvals and escalating investments in bioscience R&D activities. Moreover, rise in the generation of real world evidences, emphasis on systems medicine and patient centric care are likely to boost the outsourcing demand amongst biopharmaceutical companies across the world.
Key Players
- Indegene, Inc.
- ICON plc
- SGS S.A
- IQVIA Holdings, Inc.
- Wuxi Clinical Development, Inc.
- The Medical Affairs Company
- Zeincro Group
- Syneos Health, Inc.
- Ashfield Healthcare Communications
- Thermo Fisher Scientific Inc. (PPD)
Recent News
- MSD joined forces with Google Cloud in April 2026 to speed up AI-powered business transformation for research, manufacturing, medical operations, and healthcare work processes. The partnership includes deploying sophisticated AI technologies and cloud-based digital solutions for improved communication and information sharing in scientific research, increased operational efficiency in regulatory environments, and better management of healthcare procedures.
- In May 2026 Agilent Technologies announced a joint venture with Veeda Lifesciences aimed at establishing a center of analytical excellence in Bengaluru, India. Their collaboration seeks to enhance bioanalytical workflows, provide a GLP-ready clinical and medical data for new drugs, especially the complex biological products, as well as new treatments targeting GLP-1 therapies.
Market Segmentation
By Service
- Medical Writing & Publishing
- Medical Monitoring
- Medical Science Liaisons (MSLs)
- Medical Information
- Others
By End User
- Pharmaceutical
- Biopharmaceutical
- Medical Devices
- Therapeutic Medical Devices
- Diagnostic Medical Devices
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Looking for discounts, bulk pricing, or custom solutions? Contact us today at sales@acumenresearchandconsulting.com
Frequently Asked Questions
Related Market Research Reports
December 2022
November 2022
September 2024
April 2025
April 2025
May 2024
April 2024
March 2024